BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1009 related articles for article (PubMed ID: 23291864)

  • 1. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
    Kawano M; Itonaga I; Iwasaki T; Tsumura H
    Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma.
    Kawano M; Tanaka K; Itonaga I; Iwasaki T; Miyazaki M; Ikeda S; Tsumura H
    Oncol Rep; 2015 Oct; 34(4):1995-2001. PubMed ID: 26239052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-TGF-β antibody combined with dendritic cells produce antitumor effects in osteosarcoma.
    Kawano M; Itonaga I; Iwasaki T; Tsuchiya H; Tsumura H
    Clin Orthop Relat Res; 2012 Aug; 470(8):2288-94. PubMed ID: 22415727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrinsic and extrinsic manipulation of B7/CTLA-4 interaction for induction of anti-tumor immunity against osteosarcoma cells.
    Nagamori M; Kawaguchi S; Murakami M; Wada T; Nagoya S; Yamashita T; Inobe M; Uede T
    Anticancer Res; 2002; 22(6A):3223-7. PubMed ID: 12530068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
    Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
    J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model.
    Son CH; Bae JH; Shin DY; Lee HR; Choi YJ; Jo WS; Ho Jung M; Kang CD; Yang K; Park YS
    J Immunother; 2014 Jan; 37(1):1-7. PubMed ID: 24316550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
    Yang YF; Zou JP; Mu J; Wijesuriya R; Ono S; Walunas T; Bluestone J; Fujiwara H; Hamaoka T
    Cancer Res; 1997 Sep; 57(18):4036-41. PubMed ID: 9307290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment with dendritic cells and 5-fluorouracil elicits augmented NK cell-mediated antitumor activity through the tumor necrosis factor-alpha pathway.
    Nagasaki E; Takahara A; Koido S; Sagawa Y; Aiba K; Tajiri H; Yagita H; Homma S
    J Immunother; 2010 Jun; 33(5):467-74. PubMed ID: 20463601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
    Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
    Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer.
    Klyushnenkova EN; Riabov VB; Kouiavskaia DV; Wietsma A; Zhan M; Alexander RB
    Prostate; 2014 Oct; 74(14):1423-32. PubMed ID: 25111463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
    Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
    Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryoimmunologic antitumor effects enhanced by dendritic cells in osteosarcoma.
    Kawano M; Nishida H; Nakamoto Y; Tsumura H; Tsuchiya H
    Clin Orthop Relat Res; 2010 May; 468(5):1373-83. PubMed ID: 20232181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal.
    Lee H; Park HJ; Sohn HJ; Kim JM; Kim SJ
    J Surg Res; 2011 Jul; 169(1):e43-50. PubMed ID: 21571303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
    Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
    Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
    Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
    Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.
    Weigel BJ; Panoskaltsis-Mortari A; Diers M; Garcia M; Lees C; Krieg AM; Chen W; Blazar BR
    Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.